(Q46632523)

23 December 2017

title

Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer (English)

1 reference

23 December 2017

1 reference

J Spicer

1

1 reference

23 December 2017

T Plunkett

2

1 reference

23 December 2017

N Somaiah

3

1 reference

23 December 2017

S Chan

4

1 reference

23 December 2017

A Kendall

5

1 reference

23 December 2017

N Bolunwu

6

1 reference

23 December 2017

H Pandha

7

1 reference

23 December 2017

publication date

1 January 2005

1 reference

23 December 2017

Prostate Cancer and Prostatic Diseases

published in

1 reference

23 December 2017

volume

8

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

364-368

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500821

exact match

0 references

cites work

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Patient preferences for oral versus intravenous palliative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Hormone-refractory prostate cancer responding to capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

Assay for prostate specific antigen (PSA): problems and possible solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

7 January 2021

5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

7 January 2021

Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

7 January 2021

Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

7 January 2021

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500821

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500821

1 reference

23 December 2017

1 reference

23 December 2017